Clinical Trials

Clinical trials are how new therapies get tested and, eventually, approved. If you have a MET-altered cancer, a trial may give you access to a treatment that isn’t yet available any other way, or that addresses resistance to a therapy you’re already on.

MET Crusaders can help you navigate your options directly. Our oncology nursing staff offers one-on-one support to help you understand your results, prepare for conversations with your oncologist, and identify trials or compassionate use programs that may be relevant to your situation. Contact us at info@metcrusaders.org or call 602-618-0183.

The Pipeline: MET Drugs in Development

New MET-targeted therapies are in development across all MET alteration types and multiple tumor types. The drugs listed below as approved have completed clinical testing and received FDA approval. The pipeline is what’s still in trials, moving toward approval. For MET-altered cancers, the most active areas of pipeline research right now are next-generation ADCs, combination regimens with existing MET TKIs, and drugs that address resistance to first-line MET therapies. To search for active trials that match your specific alteration, tumor type, and treatment history, use the Clinical Trials Search below.

Standard Drugs

These are FDA-approved MET-targeted therapies. Which ones may be appropriate depends on your specific alteration, tumor type, and treatment history. See the MET Therapies page for full descriptions and links to each drug’s patient-facing website.

MET Clinical Trials & News

This page is designed to help patients and care partners find current MET-related clinical trials and updates on what is new in MET research. It covers trials across all phases, from early-phase studies where tomorrow’s treatments are being discovered to later-phase and global studies, because access to the right trial at the right time can make all the difference.

If you would like help identifying trials that match your specific MET alteration, tumor type, and treatment history, MET Crusaders can help. Contact us at info@metcrusaders.org or call 602-618-0183. You can also use the Patient Data Vault link on this page to match your profile to open trials.

Trial status can change. Before contacting a site, confirm that the trial is still enrolling and that locations in your country are active. Click the NCT number to go directly to that trial’s contacts and locations on ClinicalTrials.gov.

What’s New in MET

What we’re watching

What just happened, as of late May 2026

Current MET Clinical Trials

Trials are listed by MET alteration type. The same trial may appear in more than one section if it accepts patients with multiple MET alterations.

United States

MET Exon 14 Skipping
Recruiting

LUNG-MAP S1900K: TEPMETKO™ (tepotinib) with or without ramucirumab
For adults with stage IV or recurrent non-small cell lung cancer with a MET exon 14 skipping mutation. This randomized phase II study compares TEPMETKO alone versus TEPMETKO plus ramucirumab to see which approach better controls the cancer.
NCT06031688

SPARTA: vebreltinib (APL-101)
For adults with MET exon 14 skipping NSCLC. This global phase II study includes dedicated cohorts for first-line and previously treated patients who have not received a MET inhibitor. Vebreltinib is approved in China for MET exon 14 skipping NSCLC. U.S. sites have participated. Confirm site availability directly before making plans.
NCT03175224

Not Yet Recruiting

No MET exon 14 skipping trials with confirmed U.S. sites are currently listed as not yet recruiting.

MET Amplification
Recruiting

LUNG-MAP S1900G: TABRECTA™ (capmatinib) plus osimertinib with or without ramucirumab
For adults with EGFR-mutant, MET-amplified stage IV or recurrent non-small cell lung cancer that has progressed on osimertinib as the most recent line of therapy. This randomized phase II study tests TABRECTA plus osimertinib with or without ramucirumab.
NCT05642572

LUNG-MAP S1900J: amivantamab SC
For adults with MET amplification-positive stage IV or recurrent non-small cell lung cancer. This phase II study tests amivantamab SC, a bispecific antibody targeting EGFR and MET, given as a subcutaneous injection. Enrollment requires Foundation Medicine tissue-based next-generation sequencing, either through LUNG-MAP screening or from a prior Foundation Medicine test. Blood-based testing alone is not sufficient.
NCT06116682

SPARTA: vebreltinib (APL-101), MET amplification cohorts
SPARTA also enrolls patients with MET amplification in dedicated cohorts, including one for MET amplification with EGFR co-alterations in combination with an EGFR inhibitor. U.S. sites have participated. Confirm site availability directly before making plans.
NCT03175224

Not Yet Recruiting

No additional MET amplification trials with confirmed U.S. sites are currently listed as not yet recruiting.

MET Overexpression
Recruiting

TeliMET NSCLC-01: EMRELIS™ (telisotuzumab vedotin-tllv) versus docetaxel
For adults with previously treated, c-Met overexpressing, EGFR-wildtype, locally advanced or metastatic nonsquamous NSCLC. This global randomized phase 3 study compares EMRELIS with docetaxel. Approximately 698 patients are being enrolled across roughly 330 sites worldwide, with U.S. sites actively participating. EMRELIS is approved and available now—patients eligible for this trial may also discuss EMRELIS with their oncologist as a current treatment option.
NCT04928846

ABBV-400 (telisotuzumab adizutecan, also called Temab-A), phase 1 study in advanced solid tumors
ABBV-400 is a next-generation c-Met–targeting antibody-drug conjugate with a topoisomerase I inhibitor payload, distinct from EMRELIS. Early-phase results in previously treated nonsquamous NSCLC have been encouraging across both EGFR-mutant and EGFR wildtype patients. U.S. sites are participating, including UCLA.
NCT05029882

AndroMETa-Lung-713: ABBV-400 versus standard of care
This phase 2/3 global study compares ABBV-400 with standard of care in patients with locally advanced or metastatic EGFR-mutated nonsquamous NSCLC after progression on a third-generation EGFR TKI such as osimertinib. U.S. sites are participating, including Dana-Farber Cancer Institute.
NCT07155187

Not Yet Recruiting

EMRELIS™ plus osimertinib
For adults with EGFR-mutant, c-Met overexpressing non-small cell lung cancer that is progressing on osimertinib. This phase II study tests whether adding EMRELIS to continued osimertinib can help overcome resistance. Eligibility requires c-Met overexpression confirmed by immunohistochemistry (≥50% of tumor cells with strong 3+ staining). Patients must have progressed on osimertinib as their most recent therapy. Single site listed at UCLA. Confirm current status directly with the site before making plans.
NCT07323641

Canada

Canadian patients may have access to some of the trials listed above at Canadian sites, as well as trials not available in the U.S. All entries below should be confirmed site by site before making plans, because availability can change and some studies are international rather than Canada-specific.

MET Exon 14 Skipping and MET Amplification

TEPMETKO™ (tepotinib) in solid tumors with MET exon 14 mutation or MET amplification
Basket study of TEPMETKO in patients with solid tumors, including lung cancer, that have a MET exon 14 mutation or MET amplification.
NCT04647838

MET Overexpression

TeliMET NSCLC-01: EMRELIS™ (telisotuzumab vedotin-tllv) versus docetaxel
Same phase 3 study as in the U.S. section, for adults with c-Met overexpressing, EGFR-wildtype nonsquamous NSCLC. International sites are participating. Confirm Canadian site availability directly.
NCT04928846

International and Global Trials

These trials are led by European or Asian centers, with limited or no confirmed U.S. sites at this time. They are listed because patients outside the U.S. and Canada may be eligible, and because several are important early-phase studies where new MET treatments are being discovered. Status and site availability should be confirmed directly with the study team.

MET Exon 14 Skipping

DO-2 (DeuterOncology), brain-penetrant MET TKI
DO-2 is a deuterated, highly selective, brain-penetrant MET kinase inhibitor designed for improved tolerability over existing MET TKIs. In a phase 1 dose escalation study in MET exon 14 skipping NSCLC, evaluable patients showed strong disease control with notably low edema—a significant advantage since peripheral edema is a common and sometimes dose-limiting side effect of current MET TKIs. Dose expansion is ongoing. Sites are currently in Belgium, the Netherlands, and France. No U.S. sites are confirmed at this time.
European registry identifier: EudraCT 2022-001681-35

Developer: DeuterOncology (Belgium)
VERT-002 or PFL-002 (Pierre Fabre), c-MET degrader monoclonal antibody
A first-in-human phase I/II trial of a novel c-MET degrader monoclonal antibody that degrades the MET receptor rather than simply blocking it—a genuinely new mechanism. The study enrolls patients with locally advanced or metastatic solid tumors with MET alterations including MET exon 14 skipping and MET amplification, including patients with resistance to prior MET therapy. First patient dosed in 2024. Active sites are in France, Belgium, and Spain. A U.S. IND was filed in 2024; U.S. site opening has not been confirmed.

NCT06669117

MET Amplification and MET Overexpression

INSIGHT-2: TEPMETKO™ plus osimertinib
INSIGHT-2 is an international phase II study in EGFR-mutant NSCLC with MET amplification after progression on first-line osimertinib. It is now best viewed as important data rather than a current recruiting option, because enrollment has closed and results have been reported. The combination of TEPMETKO plus osimertinib achieved a 50% objective response rate in this setting. Results were published in The Lancet Oncology in August 2024 and the Journal of Clinical Oncology in January 2026.
NCT03940703

SAFFRON: ORPATHYS® (savolitinib) plus osimertinib — enrollment complete, global phase 3 results expected 2026
Enrollment in this global phase 3 trial is now complete (last patient randomized October 31, 2025). SAFFRON enrolled 338 patients across 230 sites in 29 countries, comparing ORPATHYS plus osimertinib versus platinum-based doublet chemotherapy in patients with EGFR-mutant NSCLC and MET overexpression and/or amplification who progressed on osimertinib. Topline results are expected in the first half of 2026. The related SACHI trial in China confirmed significant PFS improvement with the same combination and led to approval in China in June 2025. Positive SAFFRON results could support a U.S. regulatory filing for savolitinib. Watch for ASCO 2026 or ESMO 2026 presentations.
NCT05261399

Clinical Trials Search

MET Crusaders partners with Patient Data Vault, a platform that uses your health data to match your unique profile with clinical trials based on eligibility. Follow the link below to learn more and get started.

Patient Data Vault—Find a Trial

Access Pathways: Beyond Approved Therapies

Not every patient is a candidate for an approved therapy, or an approved therapy may stop working. These resources can help you and your oncologist explore what else may be available.

Lung-MAP is a clinical trial program that uses comprehensive genetic screening to match lung cancer patients to investigational treatments. Follow the link below to learn more.

Expanded Access (Compassionate Use) is a pathway that may allow patients with serious or life-threatening conditions to access investigational drugs outside of a clinical trial when no comparable approved treatment is available. Follow the link below to learn more.

Lung-MAP
Expanded Access (Compassionate Use)

Important Note
This page is for educational purposes only and is not medical advice. Clinical trial eligibility depends on biomarker results, prior treatment, location, and many other medical factors. Patients should review any trial with their oncologist and confirm current status directly with the study site.

Last reviewed: May 29, 2026.